凯信远达上涨3.03%，报1.679美元/股，总市值2601.84万美元

Core Insights - The stock price of CASI Pharmaceuticals increased by 3.03% to $1.679 per share, with a total market capitalization of $26.0184 million as of August 11 [1] - For the fiscal year ending March 31, 2025, CASI reported total revenue of $6.24 million, representing a year-over-year growth of 83.04%, while the net profit attributable to the parent company was a loss of $10.75 million, a decrease of 12.83% year-over-year [1] Company Overview - CASI Pharmaceuticals is a Nasdaq-listed biopharmaceutical company based in Rockville, Maryland, USA, focused on providing advanced treatment solutions for blood cancers in Chinese patients [2] - The company has a wholly-owned subsidiary in Beijing and joint ventures and research centers in Wuxi with local government [2] - CASI's product and research pipeline covers multiple disease areas, including multiple myeloma, B-cell non-Hodgkin lymphoma, and acute lymphoblastic leukemia [2] Upcoming Events - CASI Pharmaceuticals is scheduled to disclose its mid-year report for the fiscal year 2025 on August 15, with the actual disclosure date subject to company announcement [2]